HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

Cancer Commun (Lond). 2025 Apr;45(4):428-432. doi: 10.1002/cac2.12657. Epub 2025 Jan 6.
No abstract available

Grants and funding